NasdaqCM - Nasdaq Real Time Price ? USD NeuroBo Pharmaceuticals, Inc. (NRBO) Follow Compare 3.1600 +0.2000 (+6.76%) At close: 4:00 PM EDT 3.2800 +0.12 (+3.80%) After hours: 7:09 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for NRBO 1D 5D 27.94% 1M -8.14% 3M -34.58% 6M -7.06% YTD -14.53% 1Y -15.96% 2Y -96.90% 5Y -99.85% All -99.99% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: NRBO View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25… Zacks Small Cap Research ? 16 days ago NeuroBo Pharmaceuticals to Participate in Investor Conferences in October PR Newswire ? 16 days ago We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate Simply Wall St. ? 17 days ago NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire ? 17 days ago NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire ? last month NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24… Zacks Small Cap Research ? last month NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update PR Newswire ? 2 months ago NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial Clinical Trials Arena ? 2 months ago NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire ? 2 months ago NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity PR Newswire ? 2 months ago NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 PR Newswire ? 2 months ago View More Related Tickers PALI ? ENSC ? KPRX ? PXMD ? ATXI ? SPRC ? REVB ? ADIL ? ZVSA ? PSTV ?
